PCUR-101

N/A

Report date: 2024/04/29 14:58:55

NME

Base Information

Drug NamePCUR-101

Drug Alias NamePCUR-101

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionProto-oncogene proteins c-akt inhibitorsSignal transducer and activator of transcription 3 inhibitorsProtein kinase C epsilon type inhibitors

TargetsProto-oncogene proteins c-aktSignal transducer and activator of transcription 3Protein kinase C epsilon type

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPellficure Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPellficure Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Other Information

ATC CodeN/A